BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses

Transplantation

Volumn 92, Issue 10, 2011, Pages 1077-1084

  Blyth, Emily ^a,b   Clancy, Leighton ^b   Simms, Renee ^a   Gaundar, Shivashni ^a   O'Connell, Philip ^c   Micklethwaite, Kenneth ^a,b   Gottlieb, David J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

Adoptive T cell transfer; BK virus; BK virusassociated nephropathy; Hemopoietic stem cell transplantation; Immunotherapy; Polyomavirus; Renal transplantation; T cells

Indexed keywords

PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; VIRUS LARGE T ANTIGEN; VIRUS SMALL T ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; ARTICLE; BK VIRUS; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGENS, VIRAL; BK VIRUS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; T-LYMPHOCYTES, CYTOTOXIC;

EID: 80855129475     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31823328c0     Document Type: Article

References (21)

1. Krumbholz A, Bininda-Emonds OR, Wutzler P, et al. Phylogenetics, evolution, and medical importance of polyomaviruses. Infect Genet Evol 2009; 9: 784.
2. Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirusBKand JC infection and replication in 400 healthy blood donors. J Infect Dis 2009; 199: 837.
3. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003; 71: 115.
4. O'Donnell PH, Swanson K, Josephson MA, et al. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant 2009; 15: 1038.
5. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347: 488.
6. Hardinger KL, Koch MJ, Bohl DJ, et al. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transplant 2010; 10: 407.
7. Ramos E, Drachenberg CB, Wali R, et al. The decade of polyomavirus BK-associated nephropathy: State of affairs. Transplantation 2009; 87: 621.
8. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185.
9. Comoli P, Basso S, Labirio M, et al. T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells Mol Dis 2008; 40: 68.
10. Heslop HE, Slobod KS, Pule MA, et al. Long term outcome of EBV specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925.
11. Micklethwaite KP, Clancy L, Sandher U, et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008; 112: 3974.
12. Micklethwaite KP, Hansen A, Foster A, et al. Ex-vivo expansion and prophylactic infusion of CMV-pp65 peptide specific cytotoxic Tlymphocytes following allogeneic haemopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 707.
13. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: Implications for vaccine design. Nat Rev Immunol 2008; 8: 247.
14. Comoli P, Basso S, Azzi A, et al. Dendritic cells pulsed with polyomavirus BK antigen induce ex vivo polyoma BK virus-specific cytotoxic T-cell lines in seropositive healthy individuals and renal transplant recipients. J Am Soc Nephrol 2003; 14: 3197.
15. Harari A, Vallelian F, Meylan PR, et al. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 2005; 174: 1037.
16. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123.
17. Barker JN, Doubrovina E, Sauter C, et al. Successful treatment of EBVassociated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010; 116: 5045.
18. Balduzzi A, Lucchini G, Hirsch HH, et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant 2011; 46: 987.
19. Krymskaya L, Sharma MC, Martinez J, et al. Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides. J Virol 2005; 79: 11170.
20. Sharma MC, Zhou W, Martinez J, et al. Cross-reactive CTL recognizing two HLA-A*02-restricted epitopes within the BK virus and JC virus VP1 polypeptides are frequent in immunocompetent individuals. Virology 2006; 350: 128.
21. Lichtenfels R, Biddison WE, Schulz H, et al. CARE-LASS (calceinrelease-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J Immunol Methods 1994; 172: 227.